19:49 , Aug 4, 2017 |  BC Week In Review  |  Company News

ReNetX Bio launches with chronic SCI candidate

Neurology newco ReNetX Bio (New Haven, Conn.) launched July 24 and announced the start of a series A round to fund its first Phase I/II trial of Nogo Trap, the company’s lead candidate to treat...
23:10 , Aug 1, 2017 |  BC Extra  |  Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc. , which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio...
08:00 , Nov 16, 2015 |  BioCentury  |  Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
08:00 , Dec 10, 2012 |  BC Week In Review  |  Company News

AlphaCore Pharma LLC, Axerion Therapeutics, Optimum Therapeutics LLC, NIH cancer, cardiovascular, neurology news

NIH selected three projects for 2012 to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and Small...
02:16 , Dec 5, 2012 |  BC Extra  |  Politics & Policy

NIH selects three more projects for BrIDGs program

NIH selected three projects for 2012 to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and SBIR/STTR-eligible...
08:00 , Nov 5, 2012 |  BioCentury  |  Strategy

Racing to rebuild AZ

AstraZeneca plc 's new CEO Pascal Soriot has not yet detailed his vision for the company, but comments last month on his first call with investors coupled with an early move to halt the company's...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Axerion Therapeutics, AstraZeneca deal

Axerion granted AstraZeneca's MedImmune LLC biologics unit exclusive rights to develop and commercialize a preclinical mAb for Alzheimer's disease that inhibits the interaction between prion protein ( PRNP ; PrP; CD230 ) receptor and oligomeric...
00:52 , May 2, 2012 |  BC Extra  |  Company News

Axerion, MedImmune in deal for AD mAb

Axerion Therapeutics Inc. (New Haven, Conn.) granted MedImmune LLC exclusive rights to develop and commercialize a preclinical mAb for Alzheimer's disease that inhibits the interaction between prion protein ( PRNP ; PrP; CD230 ) receptor...
07:00 , Jul 14, 2011 |  BC Innovations  |  Targets & Mechanisms

NOGO could go far

A team of U.S. and Canadian researchers has shown that blocking production of NOGO-B in pulmonary arteries could prevent the deleterious vascular remodeling seen in pulmonary arterial hypertension. 1 If future studies demonstrate that NOGO-B...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Studies in mice and in patient samples suggest inhibiting NOGO-B could help treat pulmonary arterial hypertension (PAH)....